Our study provides thorough, mechanistic insight into the effect of systemic administration of microbial LPS on experimental SMA in terms of SMN expression, clinical disease outcomes, as well as the equilibrium between neurodegeneration and the activation of innate immunity in the CNS. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.